Key Highlights

  • Alignment Healthcare (NASDAQ:ALHC) fell 17.91% to USD 7.15 in the October 9, 2026 session, per published market data, a day after federal regulators released 2027 Medicare Advantage Star Ratings.
  • The main catalyst is that its largest contract, covering roughly three-fourths or more of members, fell below 4 stars, which removes eligibility for quality Bonus payments on that contract.
  • Published listings show October 9 analyst actions, including downgrades at BofA and William Blair and target cuts at JPMorgan and KeyBanc, though the details were not reviewed in full.
  • The company says six of seven contracts earned 4 stars or higher and reportedly plans to pursue administrative remedies, so Alignment Healthcare (NASDAQ:ALHC) faces both a ratings and a legal question.

The Ratings Cut and the Analyst Reaction

Alignment Healthcare (NASDAQ:ALHC) closed the prior session at USD 8.71 and traded at USD 7.15 in the October 9, 2026 session, down 17.91%, for a Market Value near USD 1.48 billion, per published market data. The trigger was the October 8 release of 2027 Medicare Advantage Star Ratings, in which its largest California contract fell to 3.5 stars from 4 stars. Reports said shares dropped more than 20% after hours on October 8, so those moves overlap with the October 9 figure. Published analyst-action headlines for October 9 show BofA moving to Neutral from Buy, William Blair to Market Perform, JPMorgan cutting its target to USD 10 from USD 22 and KeyBanc to USD 12 from USD 28.

How Much the Contract Matters

Contracts rated 4 stars or higher earn quality bonus payments and larger rebates, and Alignment had been an outperformer, with 100% of members in 4 star plans for 2026, as reported. The cut contract covered about 81% of membership as of September 2025, and reports now describe roughly three-fourths of about 280,000 members. Those reports say the share of members in 4 star plans is projected to drop to 25% from 98%, and TD Cowen analyst Ryan Langston estimated a Revenue loss of more than USD 170 million in 2028, a unconfirmed estimate. The company says it earned 4 stars or higher on six of seven eligible contracts and may pursue administrative remedies or litigation, which could take time and may not succeed.

Results, Guidance and Open Questions

In its July 30, 2026 release, Alignment reported second-quarter revenue of USD 1,335.6 million, up 31.6%, Net Income of USD 36.6 million and adjusted EBITDA of USD 68.1 million, with about 294,100 members. Full-year guidance called for revenue of USD 5,195 million to USD 5,225 million and adjusted EBITDA of USD 145 million to USD 163 million, set before the ratings news. Open questions include whether guidance changes, how much Margin the lost bonus removes, and whether the rating can recover. The 52-week range of roughly USD 6 to USD 25 shows how far the shares had already fallen, and the effect on payments is expected mainly in 2028.

Where Things Stand

Alignment Healthcare (NASDAQ:ALHC) fell in the October 9, 2026 session because of a verified catalyst: its largest contract lost its 4 star rating in the 2027 release on October 8, and several analysts cut views that day. The payment effect is mostly a 2028 matter, and the company disputes the rating. Watch for guidance changes, any appeal or legal action and the next quarterly report.